Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim has announced that the European Commission has granted marketing authorization of the new powerful strength of their fixed dose combination antihypertensive drug MicardisPlus 80/25 in all 27 EU member states.
Subscribe to our email newsletter
The product will be launched in Germany and Denmark in the coming weeks, followed soon by Ireland, the UK and the rest of EU, and when approved also in other countries around the world. Its co-marketing partners will market the new drug in selected countries under their own brands.
The product is licensed for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on MicardisPlus 80/12.5 (80mg telmisartan/12.5mg hydrochlorothiazide) or patients who have been previously stabilized on telmisartan and hydrochlorothiazide separately at the same dosages.